Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
P Van den Steen, B Cheuvart, Q Deraedt… - Human Vaccines & …, 2023 - Taylor & Francis
Patients with obstructive airway diseases (OAD), like chronic obstructive pulmonary disease
(COPD) and asthma, may be at increased risk of pertussis infection. Pertussis may also …
(COPD) and asthma, may be at increased risk of pertussis infection. Pertussis may also …
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2 …
S Sricharoenchai, C Sirivichayakul… - The Lancet Infectious …, 2018 - thelancet.com
Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease …
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease …
Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents
P Richmond, T Nolan, A McGirr, F Napier-Flood, J Kim… - Vaccine, 2024 - Elsevier
This phase 1 trial assessed the safety and immunogenicity of an investigational
tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg …
tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg …
Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age
R Vergara, M Tregnaghi, J Ussher, S Navarro… - European journal of …, 2005 - Springer
High rates of pertussis disease in adolescents suggest that additional boosting against
pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine …
pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine …
[HTML][HTML] A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria …
R Marlow, S Kuriyakose, N Mesaros, HH Han… - Vaccine, 2018 - Elsevier
Aim To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
acellular pertussis-inactivated poliovirus (dTap-IPV B) vaccine (Boostrix-IPV, GSK) as a pre …
Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in …
R Koepke, JC Eickhoff, RA Ayele… - The Journal of …, 2014 - academic.oup.com
Background. We estimated the vaccine effectiveness (VE) of tetanus-diphtheria-acellular
pertussis vaccine (Tdap) for preventing pertussis among adolescents during a statewide …
pertussis vaccine (Tdap) for preventing pertussis among adolescents during a statewide …
[HTML][HTML] Effectiveness of DTaP Against Pertussis in≤ 2-Year-Old Children—Linyi Prefecture, Shandong Province, China, 2017–2019
P Zhu, D Wu, Y Wang, X Liu, LE Rodewald, Y Li… - China CDC …, 2023 - ncbi.nlm.nih.gov
Vaccine effectiveness (VE) is positively correlated with the number of administered co-
purified diphtheria, tetanus, and acellular pertussis vaccine (DTaP) doses. A matched case …
purified diphtheria, tetanus, and acellular pertussis vaccine (DTaP) doses. A matched case …
Safety and immunogenicity of a national combined vaccine against pertussis, diphtheria, tetanus, hepatitis B and Hib-infection, containing acellular pertussis …
IV Feldblyum, AM Nikolaeva, KA Pavroz… - Journal of …, 2016 - microbiol.crie.ru
Aim. Study safety, reactogenicity and immunologic effectiveness of a national combined
vaccine against diphtheria, pertussis (acellular component), tetanus, hepatitis B and Hib …
vaccine against diphtheria, pertussis (acellular component), tetanus, hepatitis B and Hib …
The safety of immunizing with tetanus–diphtheria–acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a …
EA Talbot, KH Brown, KB Kirkland, AL Baughman… - Vaccine, 2010 - Elsevier
BACKGROUND: Tdap is recommended for health care personnel (HCP) aged< 65 years
who received tetanus diphtheria or tetanus toxoid immunization (Td/TT)≥ 2 years earlier …
who received tetanus diphtheria or tetanus toxoid immunization (Td/TT)≥ 2 years earlier …
Comparative trial to assess the reactogenicity of the diphtheria-tetanusacellular pertussis (DTPa) vaccine plus Haemophilus influenzae type b (Hib) conjugate vaccine …
F Calbo, R Dal-Ré, J Díez-Delgado, S Oña… - Medicina clínica, 2002 - Elsevier
BACKGROUND: The diphtheria-tetanus-whole-cell pertussis (DTPw) vaccine is being
replaced in Western countries, and inseveral Spanish Autonomous Communities, by the …
replaced in Western countries, and inseveral Spanish Autonomous Communities, by the …